Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Dow
AstraZeneca
Express Scripts
Johnson and Johnson
Mallinckrodt

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INTUNIV

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Intuniv

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00734578 Efficacy and Safety of SPD503 in Combination With Psychostimulants Completed Shire Phase 3 2008-09-01 The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.
NCT00901576 A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers Completed Shire Phase 1 2009-05-01 This is a drug-drug interaction study; the purpose of this study is to examine the pharmacokinetics (levels of drug in the blood) of SPD503 (guanfacine hydrochloride) and Concerta (methylphenidate HCl) when given alone, and in combination.
NCT00997984 Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) Completed Shire Phase 3 2009-11-01 The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from baseline score at endpoint on the ADHD-RS-IV.
NCT01069523 Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) Completed Shire Phase 4 2010-03-01 All subjects with the study will be children (age 6-12) with Attention Deficit Hyperactivity Disorder (ADHD). After baseline assessment confirms the presence of ADHD, children will have an Event related potential (ERP) (a type of electroencephalogram [EEG]) study. After the baseline EEG, children will be randomized to either placebo or GXR for a 4-week, parallel groups trial. During this trial, dosing will be flexibly adjusted according to patient response or presence of side effects. The dosage will range from 1-4 mg. At the end of the four week trial, a follow up ERP study will be obtained.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Intuniv

Condition Name

Condition Name for Intuniv
Intervention Trials
Attention Deficit Hyperactivity Disorder 6
Attention-Deficit/Hyperactivity Disorder 3
Attention Deficit Hyperactivity Disorder (ADHD) 2
ADHD 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Intuniv
Intervention Trials
Attention Deficit Disorder with Hyperactivity 15
Hyperkinesis 11
Disease 11
Anxiety Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Intuniv

Trials by Country

Trials by Country for Intuniv
Location Trials
United States 131
Canada 6
Poland 5
United Kingdom 5
Spain 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Intuniv
Location Trials
New York 8
Connecticut 7
Texas 7
Florida 7
Michigan 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Intuniv

Clinical Trial Phase

Clinical Trial Phase for Intuniv
Clinical Trial Phase Trials
Phase 4 12
Phase 3 4
Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Intuniv
Clinical Trial Phase Trials
Completed 13
Not yet recruiting 3
Recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Intuniv

Sponsor Name

Sponsor Name for Intuniv
Sponsor Trials
Shire 14
Yale University 6
New York State Psychiatric Institute 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Intuniv
Sponsor Trials
Other 27
Industry 14
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Colorcon
Moodys
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.